Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia

Por Tom, Butler, Gribben, J.G.
Publicado em 2010

Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.

Por Gimmi, C D, Freeman, G J, Gribben, J G, Gray, G, Nadler, L M
Publicado em 1993

Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.

Por Boussiotis, V A, Freeman, G J, Gribben, J G, Daley, J, Gray, G, Nadler, L M
Publicado em 1993

B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.

Por Gimmi, C D, Freeman, G J, Gribben, J G, Sugita, K, Freedman, A S, Morimoto, C, Nadler, L M
Publicado em 1991

Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Por Schultze, J L, Cardoso, A A, Freeman, G J, Seamon, M J, Daley, J, Pinkus, G S, Gribben, J G, Nadler, L M
Publicado em 1995

CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.

Por Schultze, J L, Michalak, S, Seamon, M J, Dranoff, G, Jung, K, Daley, J, Delgado, J C, Gribben, J G, Nadler, L M
Publicado em 1997

CTLA4 mediates antigen-specific apoptosis of human T cells.

Por Gribben, J G, Freeman, G J, Boussiotis, V A, Rennert, P, Jellis, C L, Greenfield, E, Barber, M, Restivo, V A, Ke, X, Gray, G S
Publicado em 1995

Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition

Por Dermit, M, Casado, P, Rajeeve, V, Wilkes, E H, Foxler, D E, Campbell, H, Critchlow, S, Sharp, T V, Gribben, J G, Unwin, R, Cutillas, P R
Publicado no Oncogene (2017)

Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-α gene promoter

Por Uglialoro, A.M., Turbay, D., Pesavento, P.A., Delgado, J.C., McKenzie, F.E., Gribben, J.G., Hartl, D., Yunis, E.J, Goldfeld, A.E.
Publicado em 1998

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)

Por Chanan-Khan, A, Egyed, M, Robak, T, Martinelli de Oliveira, F A, Echeveste, M A, Dolan, S, Desjardins, P, Blonski, J Z, Mei, J, Golany, N, Zhang, J, Gribben, J G
Publicado no Leukemia (2017)

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

Por Bühler, A, Wendtner, C-M, Kipps, T J, Rassenti, L, Fraser, G A M, Michallet, A-S, Hillmen, P, Dürig, J, Gregory, S A, Kalaycio, M, Aurran-Schleinitz, T, Trentin, L, Gribben, J G, Chanan-Khan, A, Purse, B, Zhang, J, De Bedout, S, Mei, J, Hallek, M, Stilgenbauer, S
Publicado no Blood Cancer J (2016)